Telomir Pharmaceuticals, Inc. (TELO)
Investor relations
  • Overview
  • News & Events
    • Latest from Telomir
    • Events & Conferences
    • Email Alerts
  • Company Info
    • Company Profile
    • Publications & Scientific Presentations
    • Management
    • Scientific Advisory Board
    • Contacts
    • FAQ
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote and Chart
    • Historic Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Results
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Corporate Website
Select Page

Latest from Telomir

Thu Apr 30, 2026 08:00 am

Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer

Select Year:
Tue Apr 2, 2024 08:30 am

Telomir Pharmaceuticals' Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024

Fri Mar 29, 2024 04:44 pm

UPDATE - Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

Tue Mar 26, 2024 08:30 am

Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

Fri Mar 22, 2024 08:30 am

Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th

Thu Mar 14, 2024 08:30 am

Telomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidate's Potential in DNA Age Reversal Science

Thu Mar 7, 2024 08:30 am

Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference

Tue Mar 5, 2024 08:30 am

Michael F. Roizen, MD to Increase Activities with Telomir Pharmaceuticals as Special Advisor on Age Reversal

Tue Feb 13, 2024 04:05 pm

Telomir Pharmaceuticals Announces Closing of Initial Public Offering

« Previous 1 … 4 5 6
  • Science & Research
  • Pipeline
  • Overview
  • About Us
  • ADA Compliance
  • Terms of Service
  • Youtube
  • Twitter
  • Facebook
  • Linkedin
NASDAQ: TELO
©2026 Telomir Pharmaceuticals. All Rights Reserved. This site is not intended to provide medical advice or to suggest that any product mentioned is safe or efficacious for any disease or condition.
Disclaimer

You are about to review presentations, reports and/or filings of Telomir Pharmaceuticals, Inc., that contain time-sensitive information. The information contained therein is only accurate as of the date thereof. Telomir Pharmaceuticals, Inc. will not be reviewing or updating the material that is contained in these items after the date thereof. The information contained therein may be updated, amended, supplemented or otherwise altered by subsequent presentations, reports and/or filings by Telomir Pharmaceuticals, Inc.

I Accept I Decline